PE20010288A1 - Derivados de eritropoyetina - Google Patents

Derivados de eritropoyetina

Info

Publication number
PE20010288A1
PE20010288A1 PE2000000642A PE0006422000A PE20010288A1 PE 20010288 A1 PE20010288 A1 PE 20010288A1 PE 2000000642 A PE2000000642 A PE 2000000642A PE 0006422000 A PE0006422000 A PE 0006422000A PE 20010288 A1 PE20010288 A1 PE 20010288A1
Authority
PE
Peru
Prior art keywords
conjugate
glucoprotein
erythropoyetin
amino group
group
Prior art date
Application number
PE2000000642A
Other languages
English (en)
Inventor
Josef Burg
Hans-Peter Josel
Bernd Hilger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010288A1 publication Critical patent/PE20010288A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A UN CONJUGADO QUE COMPRENDE UNA GLICOPROTEINA QUE PRESENTA AL MENOS UN GRUPO AMINO LIBRE, DE PREFERENCIA ERITROPOYETINA O SUS ANALOGOS QUE PRESENTAN LA ESTRUCTURA PRIMARIA DE LA ERITROPOYETINA MODIFICADA MEDIANTE LA ADICION DE 1-6 SITIOS DE GLUCOSILACION, DICHA GLUCOPROTEINA SE ENCUENTRA UNIDA DE FORMA COVALENTE A GRUPOS ALCOXI POLIETILENGLICOL CADA UNO SE ENCUENTRA UNIDO COVALENTEMENTE A LA GLUCOPROTEINA MEDIANTE -CO-X-S-Y-, EL CO FORMA UN ENLACE AMIDA CON EL GRUPO AMINA; X ES -(CH2)k-, (CH2(O-CH2-CH2)k; k ES 1-10; Y ES UN GRUPO a, b, ENTRE OTROS, EL PROMEDIO DEL PESO MOLECULAR DEL POLIETILENGLICOL ES DE 20 A 40 KILODALTONS, EL PESO MOLECULAR DEL CONJUGADO ES DE 51 A 175 KILODALTONS; EL CONJUGADO DE FORMULA P-[NH-CO-X-S-Y-(OCH2CH2))m-OR]m; m ES 450-900; n ES 1-3; R ES ALQUILO; P ES UNA GLUCOPROTEINA ERITROPOYETINA MENOS EL GRUPO AMINO O UN GRUPO AMINO QUE FORMA UN ENLACE AMIDA CON X; PUDIENDO SER LA GLUCOPROTEINA HUMANA O SE EXPRESA MEDIANTE LA ACTIVACION GENICA ENDOGENA; O CON UNA SECUENCIA DE 165 O 166 AMINOACIDOS; O PUEDE ESTAR MODIFICADA POR UNA SECUENCIA SELECCIONADA DE ASN30THR 32, ASN51THR53, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL CONJUGADO INCREMENTA LA PRODUCCION DE GLOBULOS ROJOS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ANEMIA POR FALLO RENAL CRONICO, CANCER, SIDA
PE2000000642A 1999-07-02 2000-06-27 Derivados de eritropoyetina PE20010288A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14224399P 1999-07-02 1999-07-02
US14745299P 1999-08-05 1999-08-05
US15145499P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
PE20010288A1 true PE20010288A1 (es) 2001-03-07

Family

ID=27385779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000642A PE20010288A1 (es) 1999-07-02 2000-06-27 Derivados de eritropoyetina

Country Status (33)

Country Link
US (1) US6340742B1 (es)
EP (1) EP1196443B1 (es)
JP (1) JP4190184B2 (es)
KR (1) KR100510624B1 (es)
CN (1) CN1194014C (es)
AR (1) AR024879A1 (es)
AT (1) ATE267840T1 (es)
AU (1) AU768452B2 (es)
BR (1) BRPI0012138B8 (es)
CA (1) CA2378533C (es)
CO (1) CO5180621A1 (es)
CZ (1) CZ301833B6 (es)
DE (1) DE60011087T2 (es)
DK (1) DK1196443T3 (es)
ES (1) ES2220501T3 (es)
GC (1) GC0000196A (es)
HK (1) HK1047597B (es)
HR (1) HRP20010966B1 (es)
HU (1) HU228478B1 (es)
IL (2) IL146956A0 (es)
JO (1) JO2291B1 (es)
MA (1) MA26806A1 (es)
MX (1) MXPA01012974A (es)
MY (1) MY126776A (es)
NO (1) NO20016304L (es)
NZ (1) NZ516170A (es)
PE (1) PE20010288A1 (es)
PL (1) PL201754B1 (es)
PT (1) PT1196443E (es)
RS (1) RS50117B (es)
TR (1) TR200103782T2 (es)
TW (1) TWI266637B (es)
WO (1) WO2001002017A2 (es)

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2359318C (en) 1999-02-01 2009-06-30 Donald Elbert Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1276849A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2001087329A1 (en) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2001092584A1 (en) * 2000-06-02 2001-12-06 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2001290312A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
JP4070605B2 (ja) 2000-10-19 2008-04-02 アイトゲノッシスシェ・テヒニッシュ・ホーホシューレ・ツューリヒ 多官能性自己集成系のためのブロックコポリマー
ATE320449T1 (de) * 2000-12-11 2006-04-15 Cheil Jedang Corp Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
ATE505204T1 (de) * 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
CN100528235C (zh) * 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
BR0207854A (pt) * 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
NZ532027A (en) * 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100480423B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
EP2324834B1 (en) * 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
WO2003055526A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
EP2277889B1 (en) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
BR0312841A (pt) * 2002-07-24 2005-12-06 Hoffmann La Roche Polipeptìdeo t1249 peguilado
AU2003250971B2 (en) * 2002-07-24 2008-04-03 F. Hoffmann - La Roche Ag Polyethylene glycol aldehyde derivatives
IL166038A0 (en) * 2002-07-24 2006-01-15 Hoffmann La Roche Pegylated t20 polypeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
MXPA05002617A (es) * 2002-09-09 2005-09-08 Warren Pharmaceuticals Inc Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
PL219741B1 (pl) * 2002-12-26 2015-07-31 Mountain View Pharmaceuticals Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004061094A1 (en) * 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
CA2509260C (en) 2002-12-31 2012-10-02 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
AU2004227937B2 (en) * 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1628686A2 (en) * 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
ATE428727T1 (de) * 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
MXPA05012313A (es) * 2003-05-12 2006-04-18 Affymax Inc Peptidos que se unen al receptor de eritropoyetina.
US7074755B2 (en) * 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) * 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
BRPI0409650A (pt) * 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
EA010650B1 (ru) * 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1694347B1 (en) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ES2815927T3 (es) 2003-12-10 2021-03-31 Nektar Therapeutics Composiciones que comprenden dos poblaciones diferentes de conjugados de polímero-agente activo
EP1696947B1 (en) * 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
WO2005063965A1 (de) 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
PT1699821E (pt) * 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
KR101439880B1 (ko) 2004-01-08 2014-09-12 라티오팜 게엠베하 펩티드의 오-결합형 글리코실화
ZA200606216B (en) * 2004-02-02 2007-11-28 Ambrx Inc Modified human interferon polypeptides and their uses
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
ES2572779T3 (es) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US20090118195A1 (en) * 2004-11-10 2009-05-07 Hans-Georg Frank Molecules Which Promote Hematopoiesis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2377884A1 (en) * 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US9505867B2 (en) 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090158449A1 (en) * 2005-08-31 2009-06-18 Kaneka Corporation Transgenic avian which has foreign gene containing sequence encoding feline-derived protein and method for production thereof
JP5198747B2 (ja) * 2005-08-31 2013-05-15 株式会社カネカ ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
CA2659990C (en) 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
JP5457185B2 (ja) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス グリセロール連結のｐｅｇ化された糖および糖ペプチド
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
WO2008057537A2 (en) * 2006-11-08 2008-05-15 Maine Medical Center Research System and method for identifying erythropoietin-responsive genes
WO2008058942A2 (en) 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
CA2682897C (en) * 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101381412B (zh) * 2007-09-30 2012-02-22 深圳赛保尔生物药业有限公司 聚合物/重组人促红素偶联物
CN101455844B (zh) * 2007-12-10 2011-09-14 江苏豪森药业股份有限公司 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009089542A2 (en) 2008-01-11 2009-07-16 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
EP2161031A1 (en) 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
KR101546563B1 (ko) 2008-12-09 2015-08-28 할로자임, 아이엔씨 연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
IN2012DN03219A (es) 2009-09-17 2015-10-23 Baxter Healthcare Sa
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
EP2616101B1 (en) 2010-09-14 2014-07-09 F.Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102453087B (zh) * 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 一种单取代peg-epo的纯化及制备方法
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
EP2720713A2 (en) 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
SG11201401797TA (en) 2011-10-24 2014-09-26 Halozyme Inc Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CA2891393A1 (en) 2012-11-20 2014-05-30 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2740805B1 (en) 2012-12-07 2019-02-20 SuppreMol GmbH Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN108289851B (zh) 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
CN109071419A (zh) 2016-03-07 2018-12-21 韩美药品株式会社 聚乙二醇衍生物及其用途
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
CN109415427A (zh) 2016-07-15 2019-03-01 豪夫迈·罗氏有限公司 用于纯化聚乙二醇化的促红细胞生成素的方法
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
KR102268647B1 (ko) 2017-06-12 2021-06-23 한국코러스 주식회사 안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
KR102497097B1 (ko) * 2017-12-29 2023-02-06 에프. 호프만-라 로슈 아게 페길화 단백질 조성물의 제공 방법
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
CN111375068B (zh) * 2018-12-29 2024-04-16 江苏豪森药业集团有限公司 聚乙二醇化多肽药物的制备方法
JP7411189B2 (ja) * 2019-03-29 2024-01-11 日油株式会社 分岐型分解性ポリエチレングリコール結合体
US20230331798A1 (en) * 2020-09-22 2023-10-19 Jecho Laboratories, Inc. Glycosylation-modified erythopoietin and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
DE3787805T2 (de) 1986-08-04 1994-02-10 Univ New South Wales Kensingto Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
EP0343635B1 (en) 1988-05-25 1994-08-24 Teijin Limited Process for continuously culturing adherent animal cells
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
DE69534676T2 (de) 1994-02-08 2006-08-17 Amgen Inc., Thousand Oaks Orale Verabreichung von chemisch modifizierten Proteinen
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0741187A2 (en) 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions

Also Published As

Publication number Publication date
MA26806A1 (fr) 2004-12-20
ATE267840T1 (de) 2004-06-15
WO2001002017A2 (en) 2001-01-11
MY126776A (en) 2006-10-31
KR100510624B1 (ko) 2005-08-31
TWI266637B (en) 2006-11-21
CZ20014682A3 (cs) 2002-11-13
PT1196443E (pt) 2004-09-30
JP4190184B2 (ja) 2008-12-03
AU6429900A (en) 2001-01-22
BRPI0012138B1 (pt) 2015-09-15
HRP20010966A2 (en) 2005-02-28
HUP0201971A3 (en) 2010-01-28
AU768452B2 (en) 2003-12-11
IL146956A0 (en) 2002-08-14
TR200103782T2 (tr) 2002-05-21
CO5180621A1 (es) 2002-07-30
ES2220501T3 (es) 2004-12-16
MXPA01012974A (es) 2002-07-30
DE60011087T2 (de) 2005-06-16
GC0000196A (en) 2006-03-29
YU89901A (sh) 2004-05-12
AR024879A1 (es) 2002-10-30
PL356065A1 (en) 2004-06-14
NO20016304L (no) 2002-02-19
CZ301833B6 (cs) 2010-07-07
CN1194014C (zh) 2005-03-23
HK1047597B (zh) 2005-08-12
JP2003503464A (ja) 2003-01-28
DK1196443T3 (da) 2004-10-04
RS50117B (sr) 2009-03-25
EP1196443A2 (en) 2002-04-17
HU228478B1 (en) 2013-03-28
NZ516170A (en) 2004-02-27
DE60011087D1 (de) 2004-07-01
CA2378533C (en) 2006-02-14
JO2291B1 (en) 2005-09-12
PL201754B1 (pl) 2009-05-29
US6340742B1 (en) 2002-01-22
NO20016304D0 (no) 2001-12-21
BR0012138A (pt) 2002-05-07
WO2001002017A3 (en) 2001-08-09
IL146956A (en) 2006-10-31
HK1047597A1 (en) 2003-02-28
BRPI0012138B8 (pt) 2021-05-25
KR20020026514A (ko) 2002-04-10
CN1359392A (zh) 2002-07-17
HRP20010966B1 (en) 2006-02-28
EP1196443B1 (en) 2004-05-26
CA2378533A1 (en) 2001-01-11
HUP0201971A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
PE20010288A1 (es) Derivados de eritropoyetina
PE20010297A1 (es) Derivados de eritropoyetina
BR9814880A (pt) HormÈnios de glicoproteìna bifuncionais de cadeia única
ATE496063T1 (de) Hybrid und tandemproteine von neisseria sp
BR0204883A (pt) Correias com costura, formadoras de imagem, que possuem adesivo de poliamida e de óxido metálico dopado entre peças de formação de costura intertravantes
DK1094816T3 (da) Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
BR9803179A (pt) Antagonistas receptores de ccr-3.
AR011204A1 (es) Compuestos analogos de lactacistina, composicion farmaceutica, uso de los mismos para la preparacion de un medicamento y metodo para inhibir laproteolisis dependiente de proteasoma
BR9811742A (pt) Compósitos de papel polirrevestido
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
GB1284935A (en) Novel polyamide derivatives suitable as retention improving agents in paper-making
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
ES2159579T3 (es) Procedimiento para la fabricacion de diisocianatos.
ES2060654T3 (es) Trigramina - un polipeptido inhibidor de la agregacion plaquetaria.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR9801043A (pt) Espumas absorvedoras de energia insufladas com água.
DE69032102D1 (de) Stabilisierte impfstoffzusammensetzungen
CO5060544A1 (es) Preparacion de poliamidas
DE69917278D1 (de) Heterocyclyl sulphonamid derivate
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
ATE21413T1 (de) Thermoplastische polyamid-zusammensetzung von hoher zaehigkeit.
ATE315577T1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
BRPI0405791A (pt) Preparados de metal nobre e preparados de lustrina para a serigrafia direta e indireta
TR199701488A2 (xx) 4-Hidroksi-piperidin t�revleri.
BR9908199A (pt) Derivados de sulfonamida

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration
FD Application declared void or lapsed